MedDataX Logo

An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

NCT ID: NCT01375478

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

197 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, over 18 years of age
* Moderate to severe rheumatoid arthritis
* RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form

Exclusion Criteria

* Patients with rheumatic autoimmune disease other than rheumatoid arthritis
* Patients who are not willing to sign the informed consent form
* Patients who participate in interventional trials during the period of this observational study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Athens, , Greece

Site Status

Athens, , Greece

Site Status

Athens, , Greece

Site Status

Crete, , Greece

Site Status

Pátrai, , Greece

Site Status

Pátrai, , Greece

Site Status

Pátrai, , Greece

Site Status

Rhodes, , Greece

Site Status

Thessaloniki, , Greece

Site Status

Thessaloniki, , Greece

Site Status

Thessaloniki, , Greece

Site Status

Thessaloniki, , Greece

Site Status

Voula, , Greece

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML25580

Identifier Type: -

Identifier Source: org_study_id